湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 证券代码：603998 证券简称：方盛制药 公告编号：2023-085 湖南方盛制药股份有限公司 | 6 | 广州御富投资有限公司 | 39.60% | 4,000 | 4,000 | | --- | --- | --- | --- | --- | | 7 | 广州脉德慎投资咨询有限公司 | 2.97% | 300 | 300 | | 8 | 北海睿智创业投资有限公司 | 29.70% | 3,000 | 3,000 | | | 合计 | 100% | 10,100 | 10,100 | 2023年10月18日，湖南方盛制药股份有限公司（以下简称"方 盛制药"或"公司"）收到珠海横琴中科建创投资合伙企业（有 限合伙）（以下简称"中科建创"）《告知函》，其合伙人珠海 横琴中科招商投资管理有限公司（以下简称"中科招商"）进行 了合伙份额的转让，公司放弃了优先受让权，所持合伙份额未发 生变动。现将有关情况公告如下： 一、本次合伙份额变动基本情况 合伙人中科招商将持有的中科建创2.48%的合伙份额（认缴 出资25 ...

湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 证券代码：603998 证券简称：方盛制药 公告编号：2023-083 湖南方盛制药股份有限公司 2023 年半年度权益 分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 本次利润分配方案经公司 2023 年 9 月 19 日的 2023 年第三次 临时股东大会审议通过。 二、 分配方案 1. 发放年度：2023 年半年度 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登 记结算有限责任公司上海分公司（以下简称"中国结算上海分公 司"）登记在册的本公司全体股东。 3. 分配方案： A 股每股现金红利 0.09 元 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2023/10/10 | － | 2023/10/11 | 2023/10 ...

湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 证券代码：603998 证券简称：方盛制药 公告编号：2023-074 湖南方盛制药股份有限公司 二、投资者提出的主要问题及公司回复情况 公司就投资者在本次说明会上提出的问题进行了回复，相关 问题及回复整理如下： 1、请问领导在目前中医的大型推广之下，公司是否会有此 意向发展呢? 尊敬的投资者，您好！公司已经形成了以中成药骨科用药、 心脑血管疾病用药、呼吸系统用药、妇科用药、儿科用药以及化 药心血管系统用药、抗感染用药等多个产品大类的产品群。后续 会发挥我们在创新中药研发与营销团队方面的优势，聚力打造大 单品，将我们已经研发成功的创新中药，如小儿荆杏止咳颗粒、 玄七健骨片等循证医学清晰、临床优秀的产品更好地进行推广。 第 1 页，共 3 页 关于2023年半年度业绩说明会召开情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 湖南方盛制药股份有限公司（以下简称"方盛制药"或"公 司"）于 2023 年 9 月 18 ...

法律意见书 广东华商（长沙）律师事务所 关于湖南方盛制药股份有限公司 2022年股权激励计划部分限制性股票 回购注销实施相关事项的 法律意见书 二〇二三年九月 法律意见书 广东华商（长沙）律师事务所 关于湖南方盛制药股份有限公司 2022年股权激励计划部分限制性股票 法律意见书 致：湖南方盛制药股份有限公司 广东华商（长沙）律师事务所（以下简称"本所"）接受湖南方盛制药股份 有限公司（以下简称"公司"或"方盛制药"）的委托，作为公司2022年限制性 股票激励计划（以下简称"本次激励计划"）项目的特聘专项法律顾问，根据《中 华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》 （以下简称"《证券法》"）及中国证券监督管理委员会（以下简称"中国证监 会"）发布的《上市公司股权激励管理办法》（以下简称"《管理办法》"）等 相关法律、法规和规范性文件以及《湖南方盛制药股份有限公司章程》（以下简 称"《公司章程》"）的有关规定，按照律师行业公认的业务标准、道德规范和 勤勉尽责精神，对公司回购注销部分激励对象已获授限制性股票实施（以下简称 "本次回购注销"）相关事项出具本法律意见书。 本所律师仅基于本 ...

湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 证券代码：603998 证券简称：方盛制药 公告编号：2023-073 湖南方盛制药股份有限公司 关于股权激励限制性股票回购注销实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 回购注销原因：因5名首次授予的激励对象离职、4名预留部分授予的激励对象 离职、48名首次授予的激励对象业绩考核结果未满足100%解禁要求，根据《方盛制药2022 年限制性股票激励计划（草案）》（以下简称"《激励计划》"）的相关规定，湖南方 盛制药股份有限公司（以下简称"公司"或"方盛制药"）对其已获授但尚未解除限售 的相应限制性股票予以回购注销，需回购注销股份数合计为551,500股。 一、本次限制性股票回购注销的决策与信息披露 1、2022年5月19日，公司召开2021年年度股东大会审议通过 了《关于提请股东大会授权董事会办理湖南方盛制药股份有限公 司2022年限制性股票激励计划有关事项的议案》，授权董事会全 权办理《激励 ...

2023 年第三次临时股东大会 会议资料 中国湖南 长沙 2023 年 9 月 19 日 湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 目 录 | 2023 | 年第三次临时股东大会会议议程 | 3 | | --- | --- | --- | | 2023 | 年第三次临时股东大会会议须知 | 5 | | 议案 | 1：关于公司 2023 年半年度利润分配方案的预案 | 6 | | 议案 | 2：关于补选公司独立董事的议案 | 7 | 第 2 页，共 7 页 湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 2023 年第三次临时股东大会会议议程 会议时间：2023 年 9 月 19 日下午 14:30 会议地点：公司办公大楼一楼会议室（一）（长沙市国家高新技术产业开发 区嘉运路 299 号） 会议召集人：公司董事会 大会主持人：董事长周晓莉女士 大会议程： ★ 签到、宣布会议开始 一、与会人员签到，领取会议资料；股东及股东代理人同时提交身份证明材 料（授权委托书、营业执照复印件、身份证复印件等 ...

Financial Performance - The company's operating revenue for the first half of 2023 was approximately RMB 855.22 million, a decrease of 2.07% compared to the same period last year [23]. - Net profit attributable to shareholders of the listed company reached approximately RMB 106.71 million, representing a significant increase of 68.86% year-on-year [23]. - The net profit after deducting non-recurring gains and losses was approximately RMB 87.49 million, an increase of 118.90% compared to the previous year [23]. - The company reported a net cash flow from operating activities of approximately -RMB 54.86 million, a decline from RMB 75.48 million in the same period last year [25]. - Total assets increased by 4.07% to approximately RMB 3.04 billion compared to the end of the previous year [25]. - Basic earnings per share for the first half of 2023 were RMB 0.25, up 66.67% from RMB 0.15 in the same period last year [25]. - The weighted average return on net assets increased by 2.24 percentage points to 7.39% compared to the previous year [25]. - The company achieved a 14.84% year-on-year growth in pharmaceutical industrial revenue, driven by enhanced product promotion and market expansion [25]. - The company has excluded the loss-making subsidiary Baijun Medical from its consolidated financial statements, which contributed to the increase in net profit [25]. - The company achieved a half-year sales revenue exceeding 100 million yuan and a net profit of over 27 million yuan, marking a significant milestone in performance [59]. Dividend and Shareholder Information - The company plans to distribute a cash dividend of 0.90 CNY per 10 shares to all shareholders on the record date, pending approval at the shareholders' meeting [5]. - The company has not proposed any capital reserve transfer to increase share capital in the profit distribution plan [5]. - The total number of shares increased by 849,000, resulting in a new total of 440,451,120 shares, with the proportion of limited sale shares rising from 2.31% to 2.50% [150]. - The company repurchased and canceled 296,000 shares of restricted stock from the 2022 incentive plan, with the cancellation completed on February 8, 2023 [151]. - A total of 1,145,000 shares of restricted stock were granted to 24 individuals, with a grant price of 2.91 yuan per share, completed on February 27, 2023 [152]. Risks and Challenges - The company has outlined various risks it may face in its operations, detailed in the management discussion and analysis section [8]. - The company faces risks from intensified market competition, with a focus on maintaining product quality and establishing a long-term quality management system [79][80]. - The establishment of a national procurement office for traditional Chinese medicine indicates a shift to nationwide procurement, leading to potential price declines for products, which may impact revenue [82]. - In the first half of 2023, the prices of traditional Chinese medicinal materials showed an upward trend, which could adversely affect the company's cost structure [82]. - The company is actively managing safety stock levels and establishing strategic reserves for key raw materials to mitigate supply risks [82]. Environmental Management - The company is classified as a key pollutant discharge unit in Changsha, with annual discharge limits for COD at 10.55 tons, ammonia nitrogen at 0.928 tons, sulfur dioxide at 0.161 tons, and nitrogen oxides at 4.032 tons [1]. - The company upgraded its wastewater treatment process to include iron-carbon micro-electrolysis, flotation, UASB anaerobic treatment, and aerobic treatment systems to meet expanding production needs [3]. - The company conducted self-monitoring of pollutants, with COD monitored every 2 hours, and ammonia nitrogen monitored quarterly, both within regulatory limits [3]. - The company received environmental credit rating as a "qualified environmental unit" from the Hunan Provincial Ecological Environment Department for 2022 [111]. - The company has established an emergency response plan for environmental incidents, registered with the local environmental authority [108]. Research and Development - Research and development expenses rose by 12.84% to ¥36.81 million, reflecting increased investment in R&D [63]. - The company has established multiple new drug research platforms, including a national-level postdoctoral research workstation and a provincial engineering technology research center [47]. - The company is currently undergoing the drug listing approval process for its innovative traditional Chinese medicine, Nolitong Granules [47]. - The company emphasizes the importance of new product development, acknowledging the high costs and long timelines associated with bringing new drugs to market [80]. Market Position and Strategy - The company completed the acquisition of controlling interest in Fangsheng Tianhong in March 2023, enhancing its market position [7]. - The company has developed a comprehensive marketing system that includes cooperation promotion, general distribution, KA/OTC distribution, and direct supply models to enhance market reach [35]. - The company ranked 63rd in the "2022 Top 100 Chinese Traditional Medicine Enterprises" and was included in the "2022-2023 Top 100 Chinese Pharmaceutical Manufacturing Enterprises" list, indicating significant growth potential [36]. - The company is focusing on cost reduction and efficiency improvement, resulting in a decrease in manufacturing costs and selling expenses [25]. - The company is actively pursuing technology transfers for various pharmaceutical products, with recent transactions valued at 74.20 million yuan and 59.36 million yuan for specific production technologies [78]. Legal Matters - The company reported a total of 255.50 million RMB in litigation liabilities related to contract disputes, with no expected impact on financial performance [135]. - The company is involved in a lawsuit concerning a loan repayment of 69.28 million RMB, which is currently in the execution phase [135]. - A total of 30.54 million RMB is involved in a contract dispute regarding rental payments, which has been settled [135]. - The company has a pending lawsuit involving a claim of 500 million RMB related to a share transfer dispute, which is currently in the execution phase [136]. - The company has reported a total of 203 million RMB in litigation liabilities from investment contract disputes, with the court ruling in favor of the company [136].

湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 证券代码：603998 证券简称：方盛制药 公告编号：2023-072 湖南方盛制药股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2023年9月18日(星期一)下午15:00-16:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于2023年9月11日(星期一)至9月15日(星期五)16:00前登录上证路演 中心网站首页点击"提问预征集"栏目或通过公司邮箱：fs88997135@126.com、 603998@fangsheng.com.cn进行提问。公司将在说明会上对投资者普遍关注的问题进行 回答。 湖南方盛制药股份有限公司（以下简称"公司"）已于 2023 年 8 月 31 ...

Financial Performance - The company's operating revenue for Q1 2023 was CNY 436,759,573.82, representing a year-on-year increase of 3.30%[3] - Net profit attributable to shareholders was CNY 63,786,808.29, showing a significant increase of 86.45% compared to the same period last year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses reached CNY 49,170,758.24, up by 100.58% year-on-year[3] - Basic earnings per share for the period was CNY 0.15, reflecting an increase of 88.21% compared to the previous year[3] - The weighted average return on equity was 4.49%, an increase of 1.67 percentage points year-on-year[3] - Total operating revenue for Q1 2023 was CNY 436,759,573.82, an increase of 3.9% compared to CNY 422,803,032.95 in Q1 2022[20] - Net profit for Q1 2023 was CNY 63,037,123.91, up 100.5% from CNY 31,343,677.50 in Q1 2022[22] - Earnings per share for Q1 2023 were CNY 0.15, compared to CNY 0.08 in Q1 2022, representing an increase of 87.5%[22] - The company reported a profit before tax of CNY 72,299,752.37, compared to CNY 35,808,330.41 in Q1 2022, an increase of 101.3%[21] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,983,131,860.61, up 2.09% from the end of the previous year[3] - As of March 31, 2023, the total assets of the company amounted to RMB 2,983,131,860.61, an increase from RMB 2,922,150,136.69 at the end of 2022, reflecting a growth of approximately 2.1%[16] - The company reported a total current liabilities of RMB 952,615,299.33, a decrease from RMB 999,587,401.38, reflecting a reduction of about 4.7%[17] - The company’s total liabilities decreased to RMB 1,255,466,225.60 from RMB 1,297,444,234.03, reflecting a decline of about 3.2%[17] - The total liabilities amounted to CNY 1,392,481,793.06, a slight decrease from CNY 1,414,201,204.10 in the previous year[18] Cash Flow - The company reported a net cash flow from operating activities of -CNY 63,977,691.55, indicating a shift from positive to negative cash flow[3] - Cash inflow from operating activities totaled CNY 378,269,536.20, down from CNY 477,571,424.27 in the previous year, a decrease of 20.8%[24] - The net cash flow from operating activities was -$63.98 million, a decrease from $39.25 million in the previous period[25] - Total cash outflow from operating activities amounted to $442.25 million, slightly up from $438.32 million year-over-year[25] - Cash inflow from investment activities totaled $47.96 million, down from $78.08 million in the previous period[25] - The net cash flow from investment activities was -$55.05 million, compared to -$35.46 million in the previous period[25] - Cash inflow from financing activities was $84.33 million, a decrease from $126.35 million year-over-year[25] - The net cash flow from financing activities was -$79.61 million, compared to a positive $19.10 million in the previous period[25] - The ending cash and cash equivalents balance was $184.79 million, down from $279.62 million in the previous period[25] Equity and Investments - Shareholders' equity attributable to the parent company increased to CNY 1,459,415,824.17, a rise of 4.98% from the previous year[3] - Total equity attributable to shareholders increased to CNY 1,459,415,824.17 from CNY 1,390,129,348.50, reflecting a growth of 5.0%[18] - The company’s long-term equity investments increased to RMB 256,735,406.63 from RMB 252,067,896.85, showing a growth of approximately 1.1%[17] - The company’s goodwill rose to RMB 273,983,187.99 from RMB 246,437,637.43, representing an increase of about 11.2%[17] Operational Changes - The increase in net profit was attributed to enhanced product marketing and academic promotion efforts, with the pharmaceutical sector achieving a revenue growth of 22.63%[5] - The company plans to continue focusing on its "338 major product development plan" to drive further growth and efficiency improvements[5] - The company established a new subsidiary, Guangdong Jida Gene Drug Engineering Research Center Co., Ltd., with a registered capital of RMB 7.3 million, holding a 73% equity stake[12] Costs and Expenses - Total operating costs decreased to CNY 383,173,514.19 from CNY 396,051,045.50, reflecting a reduction of approximately 3.5%[20] - Research and development expenses increased to CNY 17,590,859.46 from CNY 16,913,581.31, indicating a growth of 4.0%[21] - The company paid $76.40 million in employee-related cash payments, compared to $99.56 million in the previous period[25] - The company reported a total tax payment of $59.04 million, an increase from $42.57 million year-over-year[25] - Cash outflow for the acquisition of fixed assets was $55.45 million, up from $40.26 million in the previous period[25]

湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com）； 会议召开方式：上证路演中心网络互动； 证券代码：603998 证券简称：方盛制药 公告编号：2023-042 湖南方盛制药股份有限公司 关于召开2022年度业绩暨现金分红说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2023 年 5 月 17 日（星期三）下午 16:00—17:00； 第 1 页，共 2 页 投资者可于 2023 年 5 月 10 日（星期三）至 5 月 16 日（星期二）16:00 前登录上 证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 fs88997135@126.com， 603998@fangsheng.com.cn 进行提问。公司将在说明会上对投资者普遍关注的问题进行回 答。 湖南方盛制 ...